Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer

Androgen receptor (AR) is a key factor in regulation of growth and differentiation in normal and malignant prostate. Endocrine therapies for prostate cancer include inhibition of androgen production either by analogs of luteinizing hormone releasing hormone or abiraterone acetate and/or use of anti‐androgens such as hydroxyflutamide, bicalutamide, and enzalutamide. Castration therapy‐resistant cancer develops inevitably in patients who undergo treatment. AR coactivators are proteins which interact with one or more regions of the AR thus enhancing its function. Although several functions of AR coactivators may be redundant, specific functions have been identified and analyzed. The p160 group of coactivators, SRC‐1, ‐2, and ‐3 not only potentiate the activation of the AR, but are also implicated in potentiation of function of insulin‐like growth factor‐I and activation of the Akt pathway. Transcriptional integrators p300 and CBP are up‐regulated by androgen ablation and may influence antagonist/agonist balance of non‐steroidal anti‐androgens. A therapy approach designed to target p300 in prostate cancer revealed its role in regulation of proliferation of migration of androgen‐sensitive and ‐insensitive prostate cancer cells. Coactivators p300 and SRC‐1 are required for AR activation by interleukin‐6 (IL‐6), a cytokine that is overexpressed in castration therapy‐resistant prostate cancer. Some coactivators, such as Vav3, are involved in regulation of transcriptional activity of truncated AR, which emerge during endocrine thrapy. Stimulation of cellular migration and invasion by AR coactivators has also been described. Translational studies with aim to introduce anti‐AR coactivator therapy have not been successfully implemented in the clinic so far. J. Cell. Physiol. 231: 270–274, 2016. © 2015 Wiley Periodicals, Inc.